Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenapanol hydrochloride to reduce interdialysis weight gain in hemodialysis patients
jRCT1031250073Recruiting
- Sponsor
- Dokkyo Medical University Saitama Medical Center
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Single-arm trial of tenapanor in chronic kidney disease (CKD) and hyperphosphatemia, sponsored by Dokkyo Medical University Saitama Medical Center. Primary endpoint: Average total weekly weight gain. Started Dec 2024; status: recruiting.
02
Drugs
tenapanor
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on jRCT1031250073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250073.